Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

TAP To Audit Marketing Documents Related To Top Lupron, Prevacid Buyers

Executive Summary

TAP Pharmaceuticals' corporate integrity agreement with the HHS Inspector General calls for annual audits of the sales and marketing documents related to transactions with the largest volume purchasers of Lupron and Prevacid.

You may also be interested in...



Merck Marketing, Pricing Practices Lead To Settlement With Justice Dept.

Merck's $650 million settlement with the Department of Justice to resolve state and federal investigations into payment of Medicaid rebates and incentives to health care workers will act as a deterrent to other drug makers, the agency said

Merck Marketing, Pricing Practices Lead To Settlement With Justice Dept.

Merck's $650 million settlement with the Department of Justice to resolve state and federal investigations into payment of Medicaid rebates and incentives to health care workers will act as a deterrent to other drug makers, the agency said

Serostim $704 Mil. Settlement Is Largest For Off-Label Marketing Case

Serono's $704 mil. settlement over Serostim promotional practices marks the largest penalty ever paid by a pharmaceutical manufacturer to resolve civil and criminal investigations into off-label marketing

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS038648

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel